| Spectur Limited (SP3) ORDINARY FULLY PAID |
Information Technology |
$4 |
H1 FY25 Financial Statements and Appendix 4D
|
27 Feb 2025 3:20PM |
$0.012 |
$0.012 |
fallen by
0%
|
|
SP3 - Price-sensitive ASX Announcement
Full Release
Key Points
- Spectur achieved record revenue of $4.464 million for H1 FY25, a 7% increase from H1 FY24.
- Subscription revenue grew by 26% to $1.81 million.
- Rental revenue increased by 9% to $1.27 million.
- The company reported a net loss of $157,000, a 77% improvement from the previous year's loss.
- Cost optimization initiatives have significantly lowered ongoing expenses.
- Spectur is focusing on high-margin recurring revenue streams for stability and growth.
- The company transitioned to a new ERP system, reducing costs by 70%.
- Technological enhancements include improved backend software and new emergency response features.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Energy Action Limited (EAX) ORDINARY FULLY PAID |
Industrials |
$14 |
Half Year Results - Letter to Shareholders
|
27 Feb 2025 3:19PM |
$0.270 |
$0.370 |
risen by
37.04%
|
|
| Cosmo Metals Limited (CMO) ORDINARY FULLY PAID |
Materials |
$5 |
Dispatch of Entitlement Offer Prospectus
|
27 Feb 2025 3:16PM |
$0.021 |
$0.017 |
fallen by
19.05%
|
|
| Energy Action Limited (EAX) ORDINARY FULLY PAID |
Industrials |
$14 |
Half Year Results - Investor Presentation
|
27 Feb 2025 3:15PM |
$0.270 |
$0.370 |
risen by
37.04%
|
|
EAX - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 7% to $5.32 million.
- Statutory profit after tax increased by 116% to $924,259.
- EBITDA improved by 33% to $1.33 million.
- Total assets decreased by 4% to $10.046 million.
- Net assets increased by 40% to $3.258 million.
- Total liabilities reduced by 16% to $6.788 million.
- Cashflow from operating activities increased by 93% to approximately $1.41 million.
- The company's technology platform, Utilibox, is evolving to better serve customer needs.
- Focus on profitable growth and positive cashflow to decrease debt continues.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Summerset Group Holdings Limited (SNZ) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$2,457 |
Amendments to Master Trust Deed
|
27 Feb 2025 3:15PM |
$11.000 |
$10.200 |
fallen by
7.27%
|
|
| Energy Action Limited (EAX) ORDINARY FULLY PAID |
Industrials |
$14 |
Appendix 4D & Interim Financial Report
|
27 Feb 2025 3:13PM |
$0.270 |
$0.370 |
risen by
37.04%
|
|
EAX - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit after tax increased to $924,259, up 116% from the previous year.
- Total revenue declined by 7% to $5,324,156.
- Energy Management revenue increased by 6.6%, offsetting declines in other segments.
- Received a Research and Development Tax Incentive of $615,753.
- Cost reductions and operational efficiencies contributed to improved profitability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strike Energy Limited (STX) ORDINARY FULLY PAID |
Energy |
$444 |
FY25 Half Year Results Summary
|
27 Feb 2025 3:13PM |
$0.193 |
$0.155 |
fallen by
19.48%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$34 |
Appendix 4D & Half-Year Financial Statements
|
27 Feb 2025 3:13PM |
$0.155 |
$0.145 |
fallen by
6.45%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss for half-year was $1,533,422, up 32.8% from the previous year.
- Island Pharmaceuticals is focused on repurposing small molecules as antivirals.
- ISLA-101 is being advanced in a Phase 2 clinical trial for dengue fever.
- The trial is conducted in collaboration with the US Army.
- Island began recruitment for the Phase 2a/b clinical study.
- A binding Letter of Intent was executed with BioCryst for acquiring galidesivir.
- A key patent for ISLA-101 was granted by the USPTO.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wesfarmers Limited (WES) ORDINARY FULLY PAID |
Consumer Discretionary |
$94,420 |
Update - Dividend/Distribution - WES
|
27 Feb 2025 3:12PM |
$74.410 |
$83.240 |
risen by
11.87%
|
|
| Strike Energy Limited (STX) ORDINARY FULLY PAID |
Energy |
$444 |
Half Year Financial Report
|
27 Feb 2025 3:10PM |
$0.193 |
$0.155 |
fallen by
19.48%
|
|
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$37 |
Appendix 4D & Half-Year Financial Statements
|
27 Feb 2025 3:04PM |
$0.255 |
$0.165 |
fallen by
35.29%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- CYP-006TK trial completed with positive efficacy data.
- Loss for the half-year reduced to $3.65 million.
- Cash balance of $10.51 million at period end.
- Recruitment for aGvHD trial over 40% complete.
- First patient treated in kidney transplantation trial.
- Phase 3 trial for osteoarthritis completed recruitment.
- Acquisition of wound dressing technology finalized.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lynas Rare Earths Limited (LYC) ORDINARY FULLY PAID |
Materials |
$8,681 |
Lynas Rare Earths FY25 Half Year Presentation - amended
|
27 Feb 2025 3:03PM |
$6.900 |
$9.280 |
risen by
34.49%
|
|
| Lycaon Resources Limited (LYN) ORDINARY FULLY PAID |
Materials |
$8 |
Results of Meeting
|
27 Feb 2025 2:57PM |
$0.145 |
$0.130 |
fallen by
10.34%
|
|
| EMvision Medical Devices Limited (EMV) ORDINARY FULLY PAID |
Health Care |
$149 |
EMVision Releases its FY25 Half Yearly Report
|
27 Feb 2025 2:56PM |
$1.805 |
$1.740 |
fallen by
3.60%
|
|
EMV - Price-sensitive ASX Announcement
Full Release
Key Points
- EMVision announced exceptional results from the EMView pre-validation multi-centre trial.
- Diagnostic algorithms demonstrated high sensitivity and specificity in stroke detection.
- Positive feedback received from FDA on pivotal clinical trial design for emu™.
- IRB ethics approval obtained for pivotal trial in the US, designated non-significant risk.
- Pilot production line capacity for emu™ brain scanners established.
- EMVision produced first ultra-lightweight first responder proof-of-concept scanners.
- Well-funded balance sheet with cash reserves of $13.6 million as of December 31, 2024.
- Upcoming pivotal trial commencement scheduled for March 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EMvision Medical Devices Limited (EMV) ORDINARY FULLY PAID |
Health Care |
$149 |
Half Yearly Report and Accounts
|
27 Feb 2025 2:56PM |
$1.805 |
$1.740 |
fallen by
3.60%
|
|
EMV - Price-sensitive ASX Announcement
Full Release
Key Points
- EMVision reported a loss of $3,571,869 for the half-year ending December 31, 2024.
- Total income for the period was $3,807,509, a decrease from the previous year.
- The company received grant income of $1,645,576 from various funding programs.
- R&D Tax Incentive rebate income decreased to $1,694,120 this year.
- Operating expenses totaled $6,158,664, largely due to research and development costs.
- The cash outflows from operating activities increased significantly to $4,834,233.
- The company maintains a net asset position of $15,407,204 as of December 31, 2024.
- EMVision is focused on developing portable brain scanners for stroke diagnosis.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metrics Income Opportunities Trust (MOT) ORDINARY UNITS FULLY PAID |
Financials |
$654 |
Daily Fund Update
|
27 Feb 2025 2:54PM |
$2.090 |
$1.965 |
fallen by
5.98%
|
|
| Comms Group Ltd (CCG) ORDINARY FULLY PAID |
Communication Services |
$27 |
Application for quotation of securities - CCG
|
27 Feb 2025 2:45PM |
$0.057 |
$0.050 |
fallen by
12.28%
|
|
| APA Group (APA) FULLY PAID UNITS STAPLED SECURITIES |
Utilities |
$11,388 |
Change of Director's Interest Notice - Adam Watson
|
27 Feb 2025 2:44PM |
$7.545 |
$8.730 |
risen by
15.71%
|
|
| Renu Energy Limited (RNE) ORDINARY FULLY PAID |
Utilities |
$0 |
Proposed issue of securities - RNE
|
27 Feb 2025 2:43PM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,774 |
Notification regarding unquoted securities - NWS
|
27 Feb 2025 2:39PM |
$51.040 |
$49.920 |
fallen by
2.19%
|
|
| Ignite Limited (IGN) ORDINARY FULLY PAID |
Industrials |
$18 |
Application for quotation of securities - IGN
|
27 Feb 2025 2:38PM |
$1.100 |
$1.100 |
fallen by
0%
|
|
| Challenger Limited (CGF) ORDINARY FULLY PAID |
Financials |
$5,455 |
Challenger welcomes APRAs update on capital settings
|
27 Feb 2025 2:36PM |
$5.895 |
$7.890 |
risen by
33.84%
|
|
CGF - Price-sensitive ASX Announcement
Full Release
Key Points
- Challenger supports APRA's consultation on capital settings for annuity products.
- Proposed changes include a more market-sensitive illiquidity premium.
- Expected benefits include support for Australian retirees and growth in the annuity market.
- The changes could promote competition and innovation in the lifetime income market.
- Lower required capital levels for annuity products are anticipated with appropriate risk controls.
- Challenger's CEO calls this the most significant regulatory update for life insurers in 12 years.
- The changes aim to enhance financial confidence for Australians in retirement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$3,715 |
Change of Director's Interest Notice - M Scott
|
27 Feb 2025 2:33PM |
$2.500 |
$2.870 |
risen by
14.80%
|
|
| Rapid Lithium Limited (RLL) ORDINARY FULLY PAID |
Materials |
$4 |
Notification regarding unquoted securities - RLL
|
27 Feb 2025 2:28PM |
$0.004 |
$0.003 |
fallen by
25%
|
|
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$3,715 |
Change of Director's Interest Notice - DSG
|
27 Feb 2025 2:28PM |
$2.510 |
$2.870 |
risen by
14.34%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
